| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/07/2005 | US6902733 Staphylokinase derivatives with polyethyleneglycol |
| 06/07/2005 | US6902732 Nucleotid sequences coding .polypeptide for use in the treatment of inflamation and nervous system disorders |
| 06/07/2005 | US6902730 Semaphorin gene: Semaphorin W |
| 06/07/2005 | US6902729 Murine interferon-α |
| 06/07/2005 | US6902728 For treating or preventing rejection of transplanted organs, tissues or cells; particularly, use of Met-RANTES together with cyclosporin A to produce pharmaceutical composition for treatment of renal allograft transplant rejection |
| 06/07/2005 | US6902721 Inhibitors of proteasomal activity for stimulating bone growth |
| 06/07/2005 | US6902548 Injecting hyaluronidase into the vitreous humor; dose having a hyaluronidase activity of >/= 10 turbidity reducing units; accelerating the clearance of hemorrhagic blood; protease free |
| 06/07/2005 | CA2336815C Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides |
| 06/07/2005 | CA2197651C Or-1 on orphan receptor belonging to the nuclear receptor family |
| 06/07/2005 | CA2153135C Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains and compositions containing them |
| 06/07/2005 | CA2091789C Method of inhibiting microvascular thrombosis |
| 06/02/2005 | WO2005050213A1 Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer |
| 06/02/2005 | WO2005050170A2 Methods and compositions for inhibiting intracellular aggregate formation |
| 06/02/2005 | WO2005049852A2 Methods and compositions for inducing apoptosis |
| 06/02/2005 | WO2005049834A1 Cell activator, hair growth stimulant and hair growth promoter |
| 06/02/2005 | WO2005049833A1 Gene encoding g protein-coupled receptor and gene product thereof |
| 06/02/2005 | WO2005049820A1 Substance binding to transcriptional factor |
| 06/02/2005 | WO2005049819A1 Antibacterial peptide and utilization of the same |
| 06/02/2005 | WO2005049815A1 Flavivirus replication |
| 06/02/2005 | WO2005049810A1 Skeletal muscle-derived cells and methods related thereto |
| 06/02/2005 | WO2005049800A2 Methods for screening for agents capable of modulating t lymphocyte function in response to a herpes simplex virus-infected cell |
| 06/02/2005 | WO2005049792A2 Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency |
| 06/02/2005 | WO2005049650A1 Lactoferrin polypeptide, process for producing the same and inflammation inducing substance |
| 06/02/2005 | WO2005049648A2 Chimeric or fusion constructs of insulin-like growth factor binding proteins as chemotherapeutic agents |
| 06/02/2005 | WO2005049645A1 Recovery of a heat shock protein |
| 06/02/2005 | WO2005049639A2 Compositions and methods for protein isolation |
| 06/02/2005 | WO2005049105A2 Medical implants and anti-scarring agents |
| 06/02/2005 | WO2005049099A2 Fibres embedded in a glassy protein |
| 06/02/2005 | WO2005049084A2 Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure |
| 06/02/2005 | WO2005049073A2 Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients |
| 06/02/2005 | WO2005049070A1 Therapeutic use of factor xi |
| 06/02/2005 | WO2005049069A1 Excipients in drug delivery vehicles |
| 06/02/2005 | WO2005049068A1 Use of interferon tau for the treatment of obesity and for promotion of weight loss |
| 06/02/2005 | WO2005049067A1 Isolated complexes of endotoxin and md-2 |
| 06/02/2005 | WO2005049066A2 Use of dudulin2 for the treatment or prophylaxis of lung cancer |
| 06/02/2005 | WO2005049065A2 Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections |
| 06/02/2005 | WO2005049064A1 Drug therapy for celiac sprue |
| 06/02/2005 | WO2005049063A2 Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| 06/02/2005 | WO2005049062A1 Use of g-csf for treating ischemia |
| 06/02/2005 | WO2005049061A2 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
| 06/02/2005 | WO2005049055A1 Autologous treatment of degenerated disc with cells |
| 06/02/2005 | WO2005049054A1 Compositions and methods for the treatment of skin damage |
| 06/02/2005 | WO2005049027A2 Combinations useful for the treatment of neuronal disorders |
| 06/02/2005 | WO2005049014A1 Cox-2 inhibitors for the treatment or prevention of diabetes-related ocular disorders |
| 06/02/2005 | WO2005049012A2 Tryptophan for use in promoting and maintaining abstinence |
| 06/02/2005 | WO2005049006A1 Remedy for diabetes |
| 06/02/2005 | WO2005048993A2 Minimization of drug oxidation in drug irradiated excipients formulations |
| 06/02/2005 | WO2005048985A2 Alpha 1-antitrypsin compositions and treatment methods using such compositions |
| 06/02/2005 | WO2005048982A2 Efficient introduction of an aerosol into a ventilator circuit |
| 06/02/2005 | WO2005048968A1 Compositions containing mixtures of tetrapeptides and tripeptides |
| 06/02/2005 | WO2005048967A1 A method of inducing melanogenesis in humans with mc1r variant alleles |
| 06/02/2005 | WO2005048952A2 Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle |
| 06/02/2005 | WO2005048951A2 A novel human g-protein coupled receptor, hgprbmy8, expressed highly in brain |
| 06/02/2005 | WO2005048950A2 Tumor and infectious disease therapeutic compositions |
| 06/02/2005 | WO2005048949A2 Rescue agents for treating botulinum toxin intoxications |
| 06/02/2005 | WO2005048942A2 Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent |
| 06/02/2005 | WO2005048930A2 Surfactant-based gel as an injectable, sustained drug delivery vehicle |
| 06/02/2005 | WO2005048927A2 Methods and reagents for the treatment of inflammatory disorders |
| 06/02/2005 | WO2005048920A2 Methods and compositions for protecting against cataract development associated with vitrectomies |
| 06/02/2005 | WO2005048913A2 Mutant lrp5/6 wnt-signaling receptors in cancer diagnosis, prognosis and treatment |
| 06/02/2005 | WO2005034979A3 Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| 06/02/2005 | WO2005032478A3 Treatment for diabetic microvascular and macrovascular complications |
| 06/02/2005 | WO2005032470A3 Compositions and methods for treating burns |
| 06/02/2005 | WO2005030241A3 Treating inflammation using a biological agent that causes cells to release cytokine receptors |
| 06/02/2005 | WO2005026170A3 Uses of neuronal pannexins for therapy and diagnosis in mammals |
| 06/02/2005 | WO2005025497A3 Hpv cd8+ t-cell epitopes |
| 06/02/2005 | WO2005024044A3 Method for the production of fusion proteins in transgenic mammal milk |
| 06/02/2005 | WO2005023852A3 Epilancin 15x lantibiotic |
| 06/02/2005 | WO2005018659A3 Somatogenic therapy using a 20kda placental variant of growth hormone |
| 06/02/2005 | WO2005018575A3 Estrogen receptor modulators and uses thereof |
| 06/02/2005 | WO2005016958A3 Compounds for treating tumors |
| 06/02/2005 | WO2005013884A3 Methods for preventing neurological events |
| 06/02/2005 | WO2005011728A3 Use of soluble cd164 in inflammatory and/or autoimmune disorders |
| 06/02/2005 | WO2005010027A3 Novel peptidic conjugates for alopecia preventive and curative treatment |
| 06/02/2005 | WO2005000230A3 Methods of treating hyperproliferative cell disorders |
| 06/02/2005 | WO2005000192A3 Glycogen synthase kinase-3 inhibitors |
| 06/02/2005 | WO2004112572A3 Monitoring immunologic, hematologic and inflammatory diseases |
| 06/02/2005 | WO2004110470A3 Use of collagen peptides to inhibit infection |
| 06/02/2005 | WO2004103273A8 Inverse agonist and agonist peptides that stimulate/inhibit hair growth |
| 06/02/2005 | WO2004099781A3 Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor rdc1 (rdc1) |
| 06/02/2005 | WO2004096143A3 Methods for reducing or preventing transmission of nosocomial pathogens in a health care facility |
| 06/02/2005 | WO2004094601A3 Methods of treating pin1 associated disorders by covalent modification of active site residues |
| 06/02/2005 | WO2004094457A3 Stable rgd peptidomimetic composition |
| 06/02/2005 | WO2004093797A3 Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots |
| 06/02/2005 | WO2004092195A3 Dendritic cell binding proteins and uses thereof |
| 06/02/2005 | WO2004087058A3 Targeted mhc class i alpha3 vaccine delivery systems |
| 06/02/2005 | WO2004078098A3 Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases |
| 06/02/2005 | WO2004075837A3 Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| 06/02/2005 | WO2004072242A3 Screening of compounds for hematological disorder treatment |
| 06/02/2005 | WO2004071414A3 Therapeutic anti-hcv (al9) compounds |
| 06/02/2005 | WO2004066947B1 Hyperthermia oncolysis co-therapy |
| 06/02/2005 | WO2004065547A3 Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods |
| 06/02/2005 | WO2004060310A8 Human growth hormone crystals and methods for preparing them |
| 06/02/2005 | WO2004058940A9 Sirna-mediated gene silencing |
| 06/02/2005 | WO2004058154A3 Method of identifying therapeutic agents |
| 06/02/2005 | WO2004041212A3 Apkc isoforms in nervous system disorders and cancer |
| 06/02/2005 | WO2004037182A3 Active specific immunotherapy of cancer metastasis |
| 06/02/2005 | WO2004034975A3 Sustained release profile modification |
| 06/02/2005 | WO2004032855A3 Method for inhibiting angiogenesis with transforming growth factor-beta 3 inhibitors |
| 06/02/2005 | WO2004030619A3 Protein s protects the nervous system from injury |